Myelodysplastic Syndrome Clinical Trials

A listing of 58 Myelodysplastic Syndrome clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Myelodysplastic Syndrome

1 - 12 of 58

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 58 active clinical trials seeking participants for Myelodysplastic Syndrome research studies. The states with the highest number of trials for Myelodysplastic Syndrome participants are Illinois, California, Texas and New York.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Type 2 Diabetes Clinical Trial

Recruiting

Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.

Conditions:

Type 2 Diabetes

Diabetes Mellitus Type 2 in Obese

Diabetes Type Two

Type 2 Diabetes Mellitus

Diabete Type 2

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

NCT04227847

Recruiting

This trial will look at a drug called SEA-CD70 with and without azacitidine, to find out if it is safe for participants with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It will study SEA-CD70 to find out what its side effects are and if it works for AML and MDS. A side effect is anything the drug does besides treating cancer. This study will have seven groups or "parts." * Part A will find out how much SEA-CD70 should be given to participants * Part B will use the dose fou... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/12/2025

Locations: University of Alabama at Birmingham, Birmingham, Alabama +49 locations

University of Alabama at Birmingham, Birmingham, Alabama

ONeal Comprehensive Cancer Center at UAB, Birmingham, Alabama

City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California

IP Address: City of Hope Investigational Drug Services(IDS), Duarte, California

Ronald Reagan UCLA Medical Center, Los Angeles, California

UCLA Department of Medicine - Hematology & Oncology, Los Angeles, California

UCLA Hematology-Oncology Clinic, Los Angeles, California

Colorado Blood Cancer Institute, Lab, Denver, Colorado

Colorado Blood Cancer Institute, Denver, Colorado

Presbyterian/St. Luke's Medical Center, Denver, Colorado

The University of Kansas Cancer Center ,Investigational Drug Services, Fairway, Kansas

The University of Kansas Clinical Research Center, Fairway, Kansas

The University of Kansas Hospital, Kansas City, Kansas

University of Kansas Hospital Cambridge North Tower A, Kansas City, Kansas

University of Kansas Medical center Medical office building, Kansas City, Kansas

The University of Kansas Cancer Center - Overland Park, Overland Park, Kansas

The University of Kansas Cancer Center - Indian Creek Campus, Overland Park, Kansas

Norton Cancer Institute, St. Matthews Campus, Attn. Becky Champion, PharmD, Louisville, Kentucky

Norton Cancer Institute, St. Matthews Campus, Louisville, Kentucky

Norton Women & Children's Hospital, Louisville, Kentucky

Massachusetts General Hospital, Boston, Massachusetts

Beth Israel Deaconess Medical Center, Boston, Massachusetts

Karmanos Cancer Institute, Detroit, Michigan

Karmanos Cancer Institute Weisberg Cancer Treatment Center, Farmington Hills, Michigan

The University of Kansas Cancer Center - Medical Oncology Clinic, Kansas City, Missouri

The University of Kansas Cancer Center - Radiation Oncology Clinic, Kansas City, Missouri

The University of Kansas Cancer Center -North, Kansas City, Missouri

The University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri

San Juan Oncology Associates, Farmington, New Mexico

Columbia University Irving Medical Center, New York, New York

CUIMC Research Pharmacy, New York, New York

University Hospitals Cleveland Medical Center, Cleveland, Ohio

Cleveland Clinic, Cleveland, Ohio

James Cancer Hospital / Ohio State University, Columbus, Ohio

The Ohio State University Wexner Medical Center/James Cancer Hospital, Columbus, Ohio

Hollings Cancer Center, Charleston, South Carolina

Medical University of South Carolina- Ashley River Tower, Charleston, South Carolina

Medical University of South Carolina- Investigational Drug Services, Charleston, South Carolina

Medical University of South Carolina- University Hospital, Charleston, South Carolina

St. Francis Hospital, Greenville, South Carolina

St. Francis Cancer Center, Greenville, South Carolina

Baylor University Medical Center, Investigational Drug Services, Department of Pharmacy, Dallas, Texas

Baylor University Medical Center, Dallas, Texas

Houston Methodist Hospital, Houston, Texas

The University of Texas MD Anderson Cancer Center, Houston, Texas

Swedish Cancer Institute, Seattle, Washington

Swedish Medical Center, Seattle, Washington

Pharmacy - UMC Utrecht t.a.v. Apotheek KGO, Utrecht, Not set

University Medical Center (UMC) Utrecht, Utrecht, Not set

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome

Learn More ›

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

NCT06577441

Recruiting

This phase II MyeloMATCH treatment trial compares the usual treatment of cedazuridine-decitabine (ASTX727) to the combination treatment of ASTX727 and enasidenib in treating patients with higher-risk, IDH2-mutated myelodysplastic syndrome (MDS). ASTX727 is a combination of two drugs, decitabine and cedazuridine. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/10/2025

Locations: Kootenai Health - Coeur d'Alene, Coeur d'Alene, Idaho +41 locations

Kootenai Health - Coeur d'Alene, Coeur d'Alene, Idaho

Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho

Kootenai Clinic Cancer Services - Sandpoint, Sandpoint, Idaho

Illinois CancerCare-Bloomington, Bloomington, Illinois

Illinois CancerCare-Canton, Canton, Illinois

Illinois CancerCare-Carthage, Carthage, Illinois

Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois

Decatur Memorial Hospital, Decatur, Illinois

Illinois CancerCare-Dixon, Dixon, Illinois

Crossroads Cancer Center, Effingham, Illinois

Illinois CancerCare-Eureka, Eureka, Illinois

Illinois CancerCare-Galesburg, Galesburg, Illinois

Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois

Illinois CancerCare-Macomb, Macomb, Illinois

Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois

Illinois CancerCare-Pekin, Pekin, Illinois

Illinois CancerCare-Peoria, Peoria, Illinois

Illinois CancerCare-Peru, Peru, Illinois

Illinois CancerCare-Princeton, Princeton, Illinois

Southern Illinois University School of Medicine, Springfield, Illinois

Springfield Clinic, Springfield, Illinois

Springfield Memorial Hospital, Springfield, Illinois

Illinois CancerCare - Washington, Washington, Illinois

Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton, Michigan

Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton, Michigan

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea, Michigan

Cancer Hematology Centers - Flint, Flint, Michigan

Genesee Hematology Oncology PC, Flint, Michigan

Genesys Hurley Cancer Institute, Flint, Michigan

Trinity Health Saint Mary Mercy Livonia Hospital, Livonia, Michigan

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti, Michigan

Parkland Health Center - Farmington, Farmington, Missouri

Missouri Baptist Medical Center, Saint Louis, Missouri

Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri

Missouri Baptist Sullivan Hospital, Sullivan, Missouri

BJC Outpatient Center at Sunset Hills, Sunset Hills, Missouri

Billings Clinic Cancer Center, Billings, Montana

Community Medical Center, Missoula, Montana

University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Gundersen Lutheran Medical Center, La Crosse, Wisconsin

Centro Comprensivo de Cancer de UPR, San Juan, Not set

San Juan City Hospital, San Juan, Not set

Conditions: Myelodysplastic Syndrome

Learn More ›

Collection of Tissue Samples for Cancer Research

NCT00900198

Recruiting

Background: -Patients who are being evaluated and/or treated at the NIH Clinical Center and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens. Objectives: * To obtain samples from adult and pediatric patients for research purposes from tests and procedures that are done as required by the primary research protocol(s) to which a patient is enrolled or as part of their standard-of-care treatment. * To obtain samples for research purposes from non-surgical procedures, such as percutaneous biopsies, performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol. Eligibility: -Adult patients (18 years of age and older) and pediatric patients (younger than 18 years of age) who are being evaluated for and/or treated for cancer at the NIH Clinical Center participating sites. Design: * This is a multicenter tissue procurement protocol with NCI as the coordinating center. * For adult patients: specimens for research purposes, as outlined in this protocol, will be obtained from tests and procedures that are done as required by the primary research protocols to which a patient is enrolled or as part of their standard-of-care treatment. Non-surgical procedures, such as percutaneous biopsies, may also be performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol. Tissues and biological fluids to be procured may include but are not limited to blood, serum, urine, tumor tissue, normal tissue, pleural fluid, CSF, saliva, bronchial alveolar lavage (BAL), circulating tumor cells, hair follicles, and bone marrow. These specimens will be stored with unique identifiers and used to perform only those research studies that are outlined in this protocol. * For pediatric patients: tumor biopsy/resection tissue used for pediatric preclinical model development will only be from tissue already being obtained as part of a procedure necessary for the patient s clinical care or as part of a primary research protocol; blood specimens will be collected as part of a blood collection already scheduled for the patient s clinical care or as part of the planned pre-procedure bloodwork; volumes collected will not exceed institutional research limits. * Given the risks associated with any invasive procedure, such as tumor biopsy, the procedure will be discussed in detail with the patients and their parents/guardian (as indicated), including the side effects, prior to obtaining a separate consent for each procedure. A separate consent will not be signed prior to obtaining samples by minimally invasive measures, such as venipuncture. * This study has two separate consent forms at the NIH Clinical Center: one for adult patients to donate specimens for ongoing research on assay development and studies of molecular pathways, and one for adult and age-appropriate pediatric patients to donate samples for the generation of preclinical models. The study also has consent form templates for adult and pediatric patients at participating sites to donate specimens to create preclinical models. * Patients may remain on study for the duration of their consent or completion of the planned procedure, whichever comes first. Read Less

Gender:

ALL

Ages:

2 months and above

Trial Updated:

05/09/2025

Locations: UC Davis, Sacramento, California +16 locations

Conditions: Neoplasms, Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome

Learn More ›

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

NCT02115295

Recruiting

This phase II trial studies how well cladribine, idarubicin, cytarabine, and venetoclax work in patients with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blastic phase chronic myeloid leukemia. Drugs used in chemotherapy, such as cladribine, idarubicin, cytarabine, and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

05/07/2025

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Blasts 10 Percent or More of Peripheral Blood White Cells, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia

Learn More ›

Personalized NK Cell Therapy in CBT

NCT02727803

Recruiting

This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or multiple myeloma. This clinical trial will test cord blood (CB) selection for human leukocyte antigen (HLA)-C1/x recipients based on HLA-killer-cell immunoglobulin-like receptor (KIR) typing, and adoptive therapy with CB-derived NK cells for HLA-C2/C2 patients. Natural kil... Read More

Gender:

ALL

Ages:

Between 15 years and 80 years

Trial Updated:

05/07/2025

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Myeloid Leukemia With Variant MLL Translocations, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Chemotherapy-Related Leukemia, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, ISS Stage II Plasma Cell Myeloma, ISS Stage III Plasma Cell Myeloma, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Gene Mutation, Myelodysplastic/Myeloproliferative Neoplasm, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Adult Acute Lymphoblastic Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome

Learn More ›

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT05564390

Recruiting

This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is any molecule in the body that can be measured. Doctors look... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/06/2025

Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +275 locations

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

Banner University Medical Center - Tucson, Tucson, Arizona

University of Arizona Cancer Center-North Campus, Tucson, Arizona

University of Arkansas for Medical Sciences, Little Rock, Arkansas

Kaiser Permanente Dublin, Dublin, California

Kaiser Permanente-Fremont, Fremont, California

Kaiser Permanente-Fresno, Fresno, California

Tibor Rubin VA Medical Center, Long Beach, California

Cedars Sinai Medical Center, Los Angeles, California

Kaiser Permanente-Modesto, Modesto, California

Kaiser Permanente-Oakland, Oakland, California

Kaiser Permanente-Roseville, Roseville, California

Kaiser Permanente Downtown Commons, Sacramento, California

University of California Davis Comprehensive Cancer Center, Sacramento, California

Kaiser Permanente-South Sacramento, Sacramento, California

Kaiser Permanente-San Francisco, San Francisco, California

Kaiser Permanente-Santa Teresa-San Jose, San Jose, California

Kaiser Permanente San Leandro, San Leandro, California

Kaiser San Rafael-Gallinas, San Rafael, California

Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California

Kaiser Permanente-Santa Rosa, Santa Rosa, California

Kaiser Permanente-South San Francisco, South San Francisco, California

Kaiser Permanente-Vallejo, Vallejo, California

Kaiser Permanente-Walnut Creek, Walnut Creek, California

Yale University, New Haven, Connecticut

Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven, Connecticut

Augusta University Medical Center, Augusta, Georgia

Kaiser Permanente Moanalua Medical Center, Honolulu, Hawaii

Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho

Saint Luke's Cancer Institute - Boise, Boise, Idaho

Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho

Kootenai Health - Coeur d'Alene, Coeur d'Alene, Idaho

Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho

Saint Luke's Cancer Institute - Meridian, Meridian, Idaho

Saint Alphonsus Cancer Care Center-Nampa, Nampa, Idaho

Saint Luke's Cancer Institute - Nampa, Nampa, Idaho

Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho

Kootenai Clinic Cancer Services - Sandpoint, Sandpoint, Idaho

OSF Saint Joseph Medical Center, Bloomington, Illinois

Illinois CancerCare-Bloomington, Bloomington, Illinois

Illinois CancerCare-Canton, Canton, Illinois

Illinois CancerCare-Carthage, Carthage, Illinois

Northwestern University, Chicago, Illinois

University of Chicago Comprehensive Cancer Center, Chicago, Illinois

Carle at The Riverfront, Danville, Illinois

Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois

Decatur Memorial Hospital, Decatur, Illinois

Northwestern Medicine Cancer Center Kishwaukee, DeKalb, Illinois

Illinois CancerCare-Dixon, Dixon, Illinois

Carle Physician Group-Effingham, Effingham, Illinois

Crossroads Cancer Center, Effingham, Illinois

Illinois CancerCare-Eureka, Eureka, Illinois

NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois

Illinois CancerCare-Galesburg, Galesburg, Illinois

Northwestern Medicine Cancer Center Delnor, Geneva, Illinois

NorthShore University HealthSystem-Glenbrook Hospital, Glenview, Illinois

Northwestern Medicine Glenview Outpatient Center, Glenview, Illinois

Northwestern Medicine Grayslake Outpatient Center, Grayslake, Illinois

NorthShore University HealthSystem-Highland Park Hospital, Highland Park, Illinois

Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois

Northwestern Medicine Lake Forest Hospital, Lake Forest, Illinois

Illinois CancerCare-Macomb, Macomb, Illinois

Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois

Loyola University Medical Center, Maywood, Illinois

Cancer Care Center of O'Fallon, O'Fallon, Illinois

Northwestern Medicine Orland Park, Orland Park, Illinois

Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois

Illinois CancerCare-Pekin, Pekin, Illinois

Illinois CancerCare-Peoria, Peoria, Illinois

Methodist Medical Center of Illinois, Peoria, Illinois

OSF Saint Francis Medical Center, Peoria, Illinois

Illinois CancerCare-Peru, Peru, Illinois

Illinois CancerCare-Princeton, Princeton, Illinois

Southern Illinois University School of Medicine, Springfield, Illinois

Springfield Clinic, Springfield, Illinois

Springfield Memorial Hospital, Springfield, Illinois

Carle Cancer Center, Urbana, Illinois

Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois

Illinois CancerCare - Washington, Washington, Illinois

Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana

UI Health Care Mission Cancer and Blood - West Des Moines Clinic, Clive, Iowa

Mercy Medical Center - Des Moines, Des Moines, Iowa

UI Health Care Mission Cancer and Blood - Laurel Clinic, Des Moines, Iowa

University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa

University of Kansas Clinical Research Center, Fairway, Kansas

HaysMed, Hays, Kansas

University of Kansas Cancer Center, Kansas City, Kansas

Lawrence Memorial Hospital, Lawrence, Kansas

The University of Kansas Cancer Center - Olathe, Olathe, Kansas

University of Kansas Cancer Center-Overland Park, Overland Park, Kansas

University of Kansas Hospital-Indian Creek Campus, Overland Park, Kansas

Salina Regional Health Center, Salina, Kansas

Cotton O'Neil Cancer Center / Stormont Vail Health, Topeka, Kansas

University of Kansas Health System Saint Francis Campus, Topeka, Kansas

University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas

University of Kentucky/Markey Cancer Center, Lexington, Kentucky

The James Graham Brown Cancer Center at University of Louisville, Louisville, Kentucky

UofL Health Medical Center Northeast, Louisville, Kentucky

LSU Health Baton Rouge-North Clinic, Baton Rouge, Louisiana

Our Lady of the Lake Physician Group, Baton Rouge, Louisiana

Our Lady of The Lake, Baton Rouge, Louisiana

Mid Coast Hospital, Brunswick, Maine

MaineHealth Maine Medical Center - Portland, Portland, Maine

MaineHealth Cancer Care and IV Therapy - South Portland, South Portland, Maine

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland

Tufts Medical Center, Boston, Massachusetts

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor, Michigan

Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton, Michigan

Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton, Michigan

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea, Michigan

Wayne State University/Karmanos Cancer Institute, Detroit, Michigan

Henry Ford Hospital, Detroit, Michigan

Weisberg Cancer Treatment Center, Farmington Hills, Michigan

Cancer Hematology Centers - Flint, Flint, Michigan

Genesee Hematology Oncology PC, Flint, Michigan

Genesys Hurley Cancer Institute, Flint, Michigan

Hurley Medical Center, Flint, Michigan

Trinity Health Saint Mary Mercy Livonia Hospital, Livonia, Michigan

Henry Ford Medical Center-Columbus, Novi, Michigan

Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti, Michigan

Mercy Hospital, Coon Rapids, Minnesota

Essentia Health - Deer River Clinic, Deer River, Minnesota

Essentia Health Cancer Center, Duluth, Minnesota

Fairview Southdale Hospital, Edina, Minnesota

Essentia Health Hibbing Clinic, Hibbing, Minnesota

Abbott-Northwestern Hospital, Minneapolis, Minnesota

Mayo Clinic in Rochester, Rochester, Minnesota

Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota

United Hospital, Saint Paul, Minnesota

Essentia Health Virginia Clinic, Virginia, Minnesota

Baptist Memorial Hospital and Cancer Center-Golden Triangle, Columbus, Mississippi

Baptist Cancer Center-Grenada, Grenada, Mississippi

Baptist Memorial Hospital and Cancer Center-Union County, New Albany, Mississippi

Baptist Memorial Hospital and Cancer Center-Oxford, Oxford, Mississippi

Baptist Memorial Hospital and Cancer Center-Desoto, Southhaven, Mississippi

Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri

Parkland Health Center - Farmington, Farmington, Missouri

University Health Truman Medical Center, Kansas City, Missouri

University of Kansas Cancer Center - North, Kansas City, Missouri

University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri

Heartland Regional Medical Center, Saint Joseph, Missouri

Washington University School of Medicine, Saint Louis, Missouri

Mercy Hospital South, Saint Louis, Missouri

Siteman Cancer Center-South County, Saint Louis, Missouri

Missouri Baptist Medical Center, Saint Louis, Missouri

Siteman Cancer Center at Christian Hospital, Saint Louis, Missouri

Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri

Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri

Missouri Baptist Sullivan Hospital, Sullivan, Missouri

BJC Outpatient Center at Sunset Hills, Sunset Hills, Missouri

Community Hospital of Anaconda, Anaconda, Montana

Billings Clinic Cancer Center, Billings, Montana

Bozeman Health Deaconess Hospital, Bozeman, Montana

Benefis Sletten Cancer Institute, Great Falls, Montana

Logan Health Medical Center, Kalispell, Montana

Saint Patrick Hospital - Community Hospital, Missoula, Montana

Community Medical Center, Missoula, Montana

Nebraska Medicine-Bellevue, Bellevue, Nebraska

Nebraska Medicine-Village Pointe, Omaha, Nebraska

University of Nebraska Medical Center, Omaha, Nebraska

OptumCare Cancer Care at Seven Hills, Henderson, Nevada

OptumCare Cancer Care at Charleston, Las Vegas, Nevada

OptumCare Cancer Care at Fort Apache, Las Vegas, Nevada

Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey

Saint Barnabas Medical Center, Livingston, New Jersey

Monmouth Medical Center, Long Branch, New Jersey

Memorial Sloan Kettering Monmouth, Middletown, New Jersey

Memorial Sloan Kettering Bergen, Montvale, New Jersey

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

Community Medical Center, Toms River, New Jersey

University of New Mexico Cancer Center, Albuquerque, New Mexico

Montefiore Medical Center - Moses Campus, Bronx, New York

Memorial Sloan Kettering Commack, Commack, New York

Northwell Health/Center for Advanced Medicine, Lake Success, New York

North Shore University Hospital, Manhasset, New York

Mount Sinai Hospital, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

Rochester General Hospital, Rochester, New York

University of Rochester, Rochester, New York

State University of New York Upstate Medical University, Syracuse, New York

Memorial Sloan Kettering Nassau, Uniondale, New York

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina

Novant Health Presbyterian Medical Center, Charlotte, North Carolina

Duke University Medical Center, Durham, North Carolina

Novant Health Forsyth Medical Center, Winston-Salem, North Carolina

Wake Forest University Health Sciences, Winston-Salem, North Carolina

Case Western Reserve University, Cleveland, Ohio

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Providence Newberg Medical Center, Newberg, Oregon

Saint Alphonsus Cancer Care Center-Ontario, Ontario, Oregon

Providence Willamette Falls Medical Center, Oregon City, Oregon

Providence Portland Medical Center, Portland, Oregon

Providence Saint Vincent Medical Center, Portland, Oregon

Oregon Health and Science University, Portland, Oregon

Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania

Geisinger Medical Center, Danville, Pennsylvania

University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania

Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

Reading Hospital, West Reading, Pennsylvania

Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania

Rhode Island Hospital, Providence, Rhode Island

Prisma Health Cancer Institute - Spartanburg, Boiling Springs, South Carolina

Prisma Health Cancer Institute - Easley, Easley, South Carolina

Prisma Health Cancer Institute - Butternut, Greenville, South Carolina

Prisma Health Cancer Institute - Faris, Greenville, South Carolina

Prisma Health Cancer Institute - Eastside, Greenville, South Carolina

Prisma Health Cancer Institute - Greer, Greer, South Carolina

Prisma Health Cancer Institute - Seneca, Seneca, South Carolina

Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota

Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota

Baptist Memorial Hospital and Cancer Center-Collierville, Collierville, Tennessee

Baptist Memorial Hospital and Cancer Center-Memphis, Memphis, Tennessee

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas

Ben Taub General Hospital, Houston, Texas

Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah

George E Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah

University of Vermont Medical Center, Burlington, Vermont

University of Vermont and State Agricultural College, Burlington, Vermont

University of Virginia Cancer Center, Charlottesville, Virginia

Inova Schar Cancer Institute, Fairfax, Virginia

Inova Fairfax Hospital, Falls Church, Virginia

Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia

Swedish Cancer Institute-Edmonds, Edmonds, Washington

Swedish Cancer Institute-Issaquah, Issaquah, Washington

Swedish Medical Center-First Hill, Seattle, Washington

ThedaCare Regional Cancer Center, Appleton, Wisconsin

Duluth Clinic Ashland, Ashland, Wisconsin

Aurora Cancer Care-Southern Lakes VLCC, Burlington, Wisconsin

Aurora Saint Luke's South Shore, Cudahy, Wisconsin

Marshfield Medical Center-EC Cancer Center, Eau Claire, Wisconsin

Aurora Health Care Germantown Health Center, Germantown, Wisconsin

Aurora Cancer Care-Grafton, Grafton, Wisconsin

Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin

Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay, Wisconsin

Aurora BayCare Medical Center, Green Bay, Wisconsin

Aurora Cancer Care-Kenosha South, Kenosha, Wisconsin

Gundersen Lutheran Medical Center, La Crosse, Wisconsin

William S Middleton VA Medical Center, Madison, Wisconsin

University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison, Wisconsin

University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin

Aurora Bay Area Medical Group-Marinette, Marinette, Wisconsin

Marshfield Medical Center-Marshfield, Marshfield, Wisconsin

Aurora Cancer Care-Milwaukee, Milwaukee, Wisconsin

Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin

Medical College of Wisconsin, Milwaukee, Wisconsin

Aurora Sinai Medical Center, Milwaukee, Wisconsin

Marshfield Medical Center - Minocqua, Minocqua, Wisconsin

ProHealth D N Greenwald Center, Mukwonago, Wisconsin

ProHealth Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin

Saint Vincent Hospital Cancer Center at Oconto Falls, Oconto Falls, Wisconsin

Vince Lombardi Cancer Clinic - Oshkosh, Oshkosh, Wisconsin

Aurora Cancer Care-Racine, Racine, Wisconsin

Marshfield Medical Center-Rice Lake, Rice Lake, Wisconsin

Saint Vincent Hospital Cancer Center at Sheboygan, Sheboygan, Wisconsin

Vince Lombardi Cancer Clinic-Sheboygan, Sheboygan, Wisconsin

Marshfield Medical Center-River Region at Stevens Point, Stevens Point, Wisconsin

Saint Vincent Hospital Cancer Center at Sturgeon Bay, Sturgeon Bay, Wisconsin

Aurora Medical Center in Summit, Summit, Wisconsin

Vince Lombardi Cancer Clinic-Two Rivers, Two Rivers, Wisconsin

ProHealth Waukesha Memorial Hospital, Waukesha, Wisconsin

UW Cancer Center at ProHealth Care, Waukesha, Wisconsin

Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin

Aurora West Allis Medical Center, West Allis, Wisconsin

Marshfield Medical Center - Weston, Weston, Wisconsin

Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta

CancerCare Manitoba, Winnipeg, Manitoba

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario

CSSS Champlain-Charles Le Moyne, Greenfield Park, Quebec

CIUSSSEMTL-Hopital Maisonneuve-Rosemont, Montreal, Quebec

Jewish General Hospital, Montreal, Quebec

Centro Comprensivo de Cancer de UPR, San Juan, Not set

San Juan City Hospital, San Juan, Not set

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome

Learn More ›

Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia

NCT04994808

Recruiting

This phase II trials studies the effect of treosulfan-based versus clofarabine-based conditioning regimens before donor hematopoietic stem cell transplant in treating patients with myelodysplastic syndromes or acute myeloid leukemia. Chemotherapy drugs, such as treosulfan, fludarabine, and clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy and total-body irrad... Read More

Gender:

ALL

Ages:

Between 18 years and 70 years

Trial Updated:

05/01/2025

Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome

Learn More ›

A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

NCT04239157

Recruiting

This phase II trial studies how well canakinumab works for the treatment of low- or intermediate-risk myelodysplastic syndrome or chronic myelomonocytic leukemia. Canakinumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/28/2025

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome

Learn More ›

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

NCT05600894

Recruiting

This phase II trial tests whether decitabine and cedazuridine (ASTX727) in combination with venetoclax work better than ASTX727 alone at decreasing symptoms of bone marrow cancer in patients with chronic myelomonocytic leukemia (CMML), myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) with excess blasts. Blasts are immature blood cells. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/23/2025

Locations: Mayo Clinic Hospital in Arizona, Phoenix, Arizona +33 locations

Mayo Clinic Hospital in Arizona, Phoenix, Arizona

UC Irvine Health Cancer Center-Newport, Costa Mesa, California

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California

UCI Health Laguna Hills, Laguna Hills, California

Los Angeles General Medical Center, Los Angeles, California

USC / Norris Comprehensive Cancer Center, Los Angeles, California

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California

University of California Davis Comprehensive Cancer Center, Sacramento, California

Yale University, New Haven, Connecticut

Mayo Clinic in Florida, Jacksonville, Florida

Northwestern University, Chicago, Illinois

University of Chicago Comprehensive Cancer Center, Chicago, Illinois

UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois

University of Chicago Medicine-Orland Park, Orland Park, Illinois

University of Kansas Cancer Center, Kansas City, Kansas

University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas

University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland

Beth Israel Deaconess Medical Center, Boston, Massachusetts

Montefiore Medical Center-Einstein Campus, Bronx, New York

Montefiore Medical Center-Weiler Hospital, Bronx, New York

Montefiore Medical Center - Moses Campus, Bronx, New York

NYP/Weill Cornell Medical Center, New York, New York

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

Wake Forest University Health Sciences, Winston-Salem, North Carolina

University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

University of Cincinnati Cancer Center-West Chester, West Chester, Ohio

University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah

University of Virginia Cancer Center, Charlottesville, Virginia

Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia

University Health Network-Princess Margaret Hospital, Toronto, Ontario

Conditions: Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm

Learn More ›

Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant

NCT03622788

Recruiting

This phase I/II trial studies how well cytokine-treated veto cells work in treating patients with hematologic malignancies following stem cell transplant. Giving chemotherapy and total-body irradiation before a stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the patient, they may help the patient's bone marrow make stem cells, red blood cells, whit... Read More

Gender:

ALL

Ages:

Between 12 years and 75 years

Trial Updated:

04/23/2025

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia, Bone Marrow Failure, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Follicular Lymphoma, Hodgkin Lymphoma, Mantle Cell Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma

Learn More ›

Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome

NCT03672539

Recruiting

This phase II trial studies the side effects and how well liposome-encapsulated daunorubicin-cytarabine and gemtuzumab ozogamicin work in treating patients with acute myeloid leukemia that has come back (relapsed) or that does not respond to treatment (refractory) or high risk myelodysplastic syndrome. Drugs used in chemotherapy, such as liposome-encapsulated daunorubicin-cytarabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from divi... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/23/2025

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia

Learn More ›

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

NCT04708054

Recruiting

This phase II trial studies the effect of venetoclax together with busulfan, cladribine, and fludarabine in treating patients with high-risk acute myeloid leukemia or myelodysplastic syndrome who are undergoing stem cell transplant. Chemotherapy drugs, such as venetoclax, busulfan, cladribine, and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding venetoclax to the current... Read More

Gender:

ALL

Ages:

Between 18 years and 70 years

Trial Updated:

04/23/2025

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome

Learn More ›

1 - 12 of 58